Amylin Pharmaceuticals
From Wikipedia, the free encyclopedia
 |
|
| Type | Public (NASDAQ: AMLN) |
|---|---|
| Industry | Biotechnology |
| Founded | 1987 |
| Headquarters | San Diego, California, USA |
| Key people | Daniel M. Bradbury[1] |
| Products | Symlin (pramlintide) Byetta (exenatide) |
| Revenue |  US$758M (FY 2009)[2] |
| Operating income |  US$-173M (FY 2009)[2] |
| Net income | US$-186M (FY 2009)[2] |
| Total assets | US$1.73B (FY 2009)[3] |
| Total equity | US$423M (FY 2009)[3] |
| Employees | 1,900 [1] |
| Website | www.amylin.com |
Amylin Pharmaceuticals is a biopharmaceutical company based in San Diego, CA, that was founded in 1987. The company is engaged in the discovery, development and commercialization of drug candidates for the treatment of diabetes, obesity and other diseases. Currently, Amylin produces two drugs, Symlin (pramlintide acetate) and Byetta (exenatide). Amylin also is working on producing a drug based on Leptin.[4]
[edit] References
- ^ "Company Profile for Amylin Pharmaceuticals Inc (AMLN)". http://www.zenobank.com/index.php?symbol=AMLN&page=quotesearch. Retrieved 2008-10-21.
- ^ a b c Amylin Pharmaceuticals (AMLN) annual SEC income statement filing via Wikinvest.
- ^ a b Amylin Pharmaceuticals (AMLN) annual SEC balance sheet filing via Wikinvest.
- ^ Lipodystrophy Orphan Drug Program. Amylin Pharmaceuticals.
[edit] External links
 |
This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |
